Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 30, Issue 9, 2008, Pages 707-713

  Jankovic, Slobodan M ^a   Jovanovic, Dusan ^b   Milovanovic, Jasmina R ^a  

^a UNIVERSITY OF KRAGUJEVAC   (Serbia)

^b UNIVERSITY OF DEFENCE   (Serbia)

Author keywords

Carbamazepine; Epileptic patients; NONMEM; Population pharmacokinetics

Indexed keywords

CARBAMAZEPINE; VALPROIC ACID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY WEIGHT; CHILD; COMPUTER MODEL; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; SERBIA;

ADULT; AGE FACTORS; ALGORITHMS; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; CHILD; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SERBIA; VALPROIC ACID;

EID: 62649139171     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2008.30.9.1323496     Document Type: Article

References (31)

1. Bondareva, I.B., Sokolov, A.V., Tischenkova, L.F., Jelliffe, R.W. Population pharmacokinetics modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: Implication for dosage. J Clin Pharm Ther 2001, 26(3): 213-23.
2. El Desoky, E.S., Kandil, M.R. Bayesian estimation of six different sets of carbamazepine pharmacokinetic parameters in Egyptian adult epileptic patients. Pharmacol Res 2002, 45(2): 113-8.
3. Strandjord, R.E., Johannssen, S.I. Single-drug therapy with carbamazepine in patients with epilepsy: Serum levels and clinical effect. Epilepsia 1980, 21(6): 655-62.
4. Soderpalm, B. Anticonvulsants: Aspects of their mechanisms of action. Eur J Pain 2002, 6(Suppl. A): 3-9.
5. Czuczwar, S.J., Borowicz, K.K. Polytherapy in epilepsy: The experimental evidence. Epilepsy Res 2002, 52(1): 15-23.
6. Almeida, A.M., Falcão, A.C., Sales, F. et al. Kinetic profile of carbamazepine in an adult Portuguese outpatient population. J Clin Pharm Ther 1998, 23(4): 315-21.
7. Brodie, M.J., Dichter, M.A. Drug therapy. N Engl J Med 1996, 334(3): 168-75.
8. Patsalos, P.N., Fröscher, W., Pisani, F., van Rijn, C.M. The importance of drug interaction in epilepsy therapy. Epilepsia 2002, 43(4): 365-85.
9. Hata, M., Tanaka, Y., Kyoda, N. et al. An epoxidation mechanism of carbamazepine by CYP3A4. Bioorg Med Chem 2008, 16(9): 5134-48.
10. Eadie, M.J. Therapeutic drug monitoring - Antiepileptic drugs. Br J Clin Pharmacol 1998, 46(3): 185-93.
11. Milovanovic, J.R., Jankovic, S.M. [Population pharmacokinetics] (in Serbian). Vojnosanit Pregl 2005, 62(11): 847-50.
12. Aarons, L. Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1999, 36(4): 255-64.
13. Ette, E.I., Williams, P.J. Population pharmacokinetics II: Estimation methods. Ann Pharmacother 2004, 38(11): 1907-15.
14. Lindbom, L., Ribbing, J., Jonson, E.N. Perl-speaks-NONMEM (PsN)-A Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004, 75(2): 85-94.
15. Beal, S.L., Shemer, L.B. NONMEM Users Guides. NONMEM Project Group. University of California, San Francisco, 1998.
16. Yukawa, E. Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical care of patients. J Clin Pharm Ther 1999, 24(2): 103-13.
17. Sheiner, L.B., Beal, S.L. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981, 9(4): 503-12.
18. Pokrajac, M. Population pharmacokinetics. In: Pharmacokinetics. Pokrajac, M. (Ed.). Grafolik, Beograd, 2002, 185-6.
19. Sander, J.W. The use of antiepileptic drugs Principles and practice. Epilepsia 2004, 45(6): 28-34.
20. Nassiri, R., Stelmasiak, Z. Pharmacotherapy of epilepsy. Neurol Neurochir Pol 2000, 34(8): 47-58.
21. Jankovic, S.M., Milovanovic, J.R. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients. Methods Find Exp Clin Pharmacol 2007, 29(10): 673-9.
22. Jiao, Z., Zhong, M.K., Shi, X.J., Hu, M., Zhang, J.H. Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. Ther Drug Monit 2003, 25(3): 279-86.
23. Gray, A.L., Botha, J.H., Miller, R. A model for determination of carbamazepine clearance in children on mono- and polytherapy. Eur J Clin Pharmacol 1998, 54(4): 359-62.
24. Radovanovic, R.V., Djordjevic. A.C., Dimic, M. [Clinically significant pharmacokinetic interactions of antiepileptic drugs] (in Serbian). Acta Med Medianae 2007, 46: 55-60.
25. Jankovic, S.M., Prostran, M., Todorovic, Z. Pharmacology and Toxicology. Medical Faculty, University of Kragujevac, Kragujevac and Belgrade. Serbia, 2007.
26. Varagic, V., Milosevic, M. Pharmacology. Elit-Medica, Beograd, 2007.
27. Delgado Iribanegaray, M.F., Santos Buelga, D., Garcia Sanchez, M.J., Olero, M.J., Falcão, A.C., Domínguez-Gil, A. Carbamazepine population pharmacokinetics in children: Mixed-effect models. Ther Drug Monit 1997, 19: 132-9.
28. Jiao, Z., Shi, X.J., Zhao, Z.G., Zhong, M.K. Population pharmacokinetic modeling of steady slate clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data. J Clin Pharm Ther 2004, 29(3): 247-56.
29. Chan, E., Lee, H.S., Hue, S.S. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. Br J Clin Pharmacol 2001, 51(6): 567-76.
30. Baciewicz, A.M. Carbamazepine drug interaction. Ther Drug Monit 1986, 8(3): 305-17.
31. Yukawa, E., Aoyama, T. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J Clin Pharmacol 1996, 36(8): 752-9.